Wall Street analyst estimates for Lantern Pharma Inc. (LTRN): consensus price target, buy/hold/sell recommendations and forecasts for revenue, EPS and EBITDA for the upcoming fiscal years.
Lantern Pharma Inc. is a clinical-stage biotechnology firm dedicated to revolutionizing drug development through the strategic application of artificial intelligence, machine learning, and comprehensive genomic data analysis. Their primary drug candidate, LP-100, is currently undergoing Phase II clinical trials, targeting metastatic, castration-resistant prostate cancer.
Valuation Ratios
| Price / Book | -7.45 |
| EV / EBITDA | -0.90 |
| Dividend Yield | 0.00% |
Income Statement (10y)
| Year | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | -$2544 | $1627 | 0 | 0 | 0 | $174843 | 0 | 0 |
| Gross Profit | $2544 | -$1627 | 0 | 0 | 0 | -$174843 | 0 | 0 |
| Research & Development | $572095 | $953185 | $2.2M | $7.6M | $8.60B | $11.9M | $16.1M | $11.5M |
| Selling, General & Admin | $1.2M | $1.5M | $3.7M | $5.0M | $5.83B | $6.0M | $6.1M | $6.5M |
| Operating Expenses | $1.7M | $2.4M | $5.9M | $12.6M | $14.43B | $17.7M | $22.2M | $18.0M |
| Operating Income | -$1.7M | -$2.4M | -$5.9M | -$12.6M | -$14.43B | -$17.9M | -$22.2M | -$18.0M |
| EBITDA | -$1.7M | -$2.4M | -$5.9M | -$12.4M | -$14.26B | -$15.8M | -$20.8M | -$17.1M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Pre-tax Income | -$1.7M | -$2.4M | -$5.9M | -$12.4M | -$14.26B | -$16.0M | -$20.8M | -$17.1M |
| Income Tax | $2544 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Income | -$1.7M | -$2.4M | -$5.9M | -$12.4M | -$14.26B | -$16.0M | -$20.8M | -$17.1M |
| EPS | $-0.28 | $-0.39 | $-0.95 | $-1.13 | $-1.31 | $-1.47 | $-1930.92 | $-1.57 |
| EPS (Diluted) | $-0.28 | $-0.39 | $-0.95 | $-1.13 | $-1.31 | $-1.47 | $-1930.92 | $-1.57 |
| Shares Outstanding (Diluted) | $6.2M | $6.3M | $6.2M | $10.9M | $10.9M | $10.8M | $10.8M | $10.9M |
Price
| Price | $1.93 |
| Market Cap | $25M |
| Exchange | NASDAQ |
| Country | US |
Related companies: ANVS · ATNM · BCAB · CALC · ELUT · LVTX · MAIA
Explore sector: Healthcare · Biotechnology
More sections of LTRN: Overview · Financials · Valuation · Statistics · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks